RCEL Insider Purchase: CFO David O'Toole Adds 2,000 Shares

Rhea-AI Filing Summary

Insider purchase reported: Avita Medical (RCEL) CFO David O'Toole purchased 2,000 shares of the company's common stock on 08/26/2025 at a price of $4.52 per share. After the transaction he beneficially owns 31,657 shares in a direct capacity. The filing shows no amendments and no derivative transactions were reported.

Insights

Financial Analyst

TL;DR: A routine insider purchase by the CFO increased direct holdings to 31,657 shares; transaction size appears modest relative to typical market-moving events.

David O'Toole, identified as CFO, reported a purchase of 2,000 common shares at $4.52 on 08/26/2025, bringing his direct beneficial ownership to 31,657 shares. This Form 4 displays a straightforward open-market acquisition with no associated derivatives or exercise events. The disclosure is timely and complies with Section 16 reporting requirements. Given the small size of the purchase, the trade is unlikely to be material on its own but reflects an insider acquisition.

Corporate Governance Expert

TL;DR: Insider purchase by a named officer is a positive governance signal but not materially significant given the modest share amount.

The filing shows the CFO executed a purchase (code P) for 2,000 shares and signed the Form 4 on 08/26/2025. The transaction is reported as direct ownership and there are no indications of 10b5-1 plan usage or related derivative instruments. From a governance perspective, timely disclosure and direct acquisition by an executive support alignment with shareholder interests, though the absolute size is limited.

Insider Trade Summary

Net Buyer: 2,000 shares

Net Buy 1 txn

Insider O'Toole David D

Role CFO

Bought 2,000 shs ($9K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,000	$4.52	$9K

Holdings After Transaction: Common Stock — 31,657 shares (Direct)

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 08/26/2025 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Toole David D

(Last) (First) (Middle)

28159 AVENUE STANFORD

SUITE 220 - AVITA MEDICAL

(Street)

VALENCIA CA 91355

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AVITA Medical, Inc. [ RCEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/26/2025		P		2,000	A	$4.52	31,657	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	David O'Toole	08/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.